Page 6 - Institut Gustave Roussy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Tedopi: positive results for a lung cancer vaccine

One year after the start of treatment, 44.1% of these patients were still alive in the group receiving the vaccine, compared with only 27.5% in the chemotherapy group, according to the results of a phase 3 clinical trial

United statesBenjamin besseNicolas poirierInstitut gustave roussyClinical researchProfessor benjamin besse

Alcatel-Lucent Enterprise and Nokia on board for Grand Paris rail project

Technology for Good partnership between leading Alcatel-Lucent Enterprise and Nokia supports transportation service in the Grand Paris area.

Le bourgetFrance generalUnited kingdomInstitut gustave roussyRukmini glanardNathan stensonPlaine saint denisTechnology for goodAlcatel lucent enterpriseGrand paris expressGrand parisCharles de gaulle

Black lesbian eco-feminists fight for victims of Caribbean pesticide poisoning

Black lesbian eco-feminists fight for victims of Caribbean pesticide poisoning
76crimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from 76crimes.com Daily Mail and Mail on Sunday newspapers.

France generalFrench west indiesGuadeloupe generalAnne souyrisMalcom ferdinandMathilde panotLaurent sorelPierrette pyram ambrosioInstitut gustave roussyParis city council onParis city hallParis city councilWest indianWest indiansPlace de la nationAlice coffin

Appia Bio Expands Leadership Team With Sylvaine Cases, Ph D Appointed Chief Business Officer and Alex Babayan, Ph D as Vice President, Head of Regulatory Affairs

Appia Bio Expands Leadership Team With Sylvaine Cases, Ph D Appointed Chief Business Officer and Alex Babayan, Ph D as Vice President, Head of Regulatory Affairs
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

University of southern californiaUnited statesSan franciscoLos angelesAlex babayanAppia bioDavid baltimoreInstitut gustave roussyLili yangPrnewswire appia bio incUniversity of californiaCancer researchVillejuif university of parisJohnson oncologyInstil bioAppia cells utilized

Janssen s Erdafitinib significantly extends survival of urothelial cancer

The Janssen Pharmaceutical Companies of Johnson & Johnson announced its drug Erdafitinib extends survival in bladder cancer.

France generalInstitut gustave roussyYohann loriotJanssen cilag gmbMartin vogelEastern cooperative oncology groupUniversity of parisJanssen cilag gmbhClinical developmentPis active pharmaceutical ingredientsPhase iii ivBladder cancerClinical trialClinical researchPharmaceutical industry